Publication Tehrani S, Mediterr J Infect Microbes Antimicrob (2022) (published paper)
Dates: 2021-04-01 to 2021-09-30
Funding: No specific funding (The authors declared that this study received no financial support.)
Conflict of interest: No
Single center / Iran |
Follow-up duration (days): 6
Initial dose: 1600 mg favipiravir orally 2 times a day for the first 24 hours -Maintenance dose: 600 mg orally 2 times a day for the next 4 days.
|Characteristics of participants|
Mean age : NR
Severity : Mild: n= 78/ Asymptomatic: n=0
Number of vaccinated participants: NR
|In the register|
1) Body temperature; Timepoint: Days 1 (start of treatment), 3, 5 and 7; Method of measurement: Thermometer. 2) Respiratory rate (per minute); Timepoint: Days 1 (start of treatment), 3, 5 and 7; Method of measurement: Physical examination by physician. 3) Oxygen saturation; Timepoint: Days 1 (start of treatment), 3, 5 and 7; Method of measurement: Pulseoxymeter.
|In the report|
Hospitalization rate during the seven-days follow-up period.
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
|General comment||In addition to the published article, the study registry was used in data extraction. The study achieved the target sample size specified in the trial registry. There is no change from the trial registration in the intervention and control treatments. The registry primary outcome does not reflect the reported primary outcome. Adverse events did not seem to be completely reported. The study duration was short.|